February 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted approval by US FDA for the company's IND application for BRG01 cell therapy, path the way for Phase I/II clinical trial. BRG01 is an autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer (NPC) treatment. The prin...

SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas

On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as “Biosyngen”) made an announcement on the approval granted by the Center for Drug Evaluation (CDE) of China’s National Medical Products

Biosyngen featured in the “Top 50 Most Innovative Companies of Chinese Biomedicine in 2022”, Pharma BigstarOn November 10th to 11th, 2022, the Shanghai (Minhang) Biopharmaceutical Industry Innovation

Prof. Jean Paul Thiery, Biosyngen’s Chief Scientist, is ranked among the World’s Top 2% Clinical Scientists 2022Professor Jean Paul Thiery, Biosyngen’s Chief Scientist and Chairman of Scientific Advis

SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas

SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas

SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas

SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas